The genomic complexity underlying pulmonary arterial hypertension: From mendel to networks

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 10, 2014, Pages 1152-1154

  Rajkumar, Revathi ^a   Ahmad, Ferhaan ^b  

^a ILLUMINA INC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CYTOCHROME P450 1B1; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 6; LONG UNTRANSLATED RNA; MESSENGER RNA; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; CELL INTERACTION; CPG ISLAND; DNA FLANKING REGION; DNA METHYLATION; EDITORIAL; ENDOTHELIUM CELL; ENVIRONMENTAL EXPOSURE; EPIGENETICS; ESTROGEN URINE LEVEL; FAMILY HISTORY; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN; IN VITRO STUDY; LUNG ARTERY PRESSURE; LUNG PARENCHYMA; METABOLOMICS; PATHOPHYSIOLOGY; PENETRANCE; PERSONALIZED MEDICINE; PHENOTYPE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEOMICS; PULMONARY HYPERTENSION; RARE DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; SOMATIC MUTATION; SYSTEMS BIOLOGY; THROMBOCYTE AGGREGATION; VARIABLE NUMBER OF TANDEM REPEAT; WILD TYPE;

EID: 84901020424     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201404-0632ED     Document Type: Editorial

References (18)

1. Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet 2014;133:471-479.
2. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005;111:534-538.
3. Austin ED, Hamid R, Ahmad F. Somatic mutations in pulmonary arterial hypertension: primary or secondary events? Am J Respir Crit Care Med 2010;182:1094-1096.
4. Stearman RS, Cornelius AR, Lu X, Conklin DS, Del Rosario MJ, Lowe AM, Elos MT, Fettig LM, Wong RE, Hara N, et al. Functional prostacyclin synthase promoter polymorphisms: impact in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014;189: 1110-1120.
5. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006;15:502-508.
6. Iwai N, Katsuya T, Ishikawa K, Mannami T, Ogata J, Higaki J, Ogihara T, Tanabe T, Baba S. Human prostacyclin synthase gene and hypertension: the Suita Study. Circulation 1999;100:2231-2236.
7. Yokoyama C, Yabuki T, Inoue H, Tone Y, Hara S, Hatae T, Nagata M, Takahashi EI, Tanabe T. Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics 1996;36:296-304.
8. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103:1509-1515.
9. Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol 2013;111(5 Suppl):1A-16A, quiz 17A-19A.
10. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-1932.
11. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA III. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009;34:1093-1099.
12. Phillips JA III, Poling JS, Phillips CA, Stanton KC, Austin ED, Cogan JD, Wheeler L, Yu C, Newman JH, Dietz HC, et al. Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension. Genet Med 2008;10:359-365.
13. Willers ED, Newman JH, Loyd JE, Robbins IM, Wheeler LA, Prince MA, Stanton KC, Cogan JA, Runo JR, Byrne D, et al. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;173: 798-802.
14. Germain M, Eyries M, Montani D, Poirier O, Girerd B, Dorfmüller P, Coulet F, Nadaud S, Maugenre S, Guignabert C, et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet 2013;45:518-521.
15. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 2007;292:C1837-C1853.
16. Tanabe N, Amano S, Tatsumi K, Kominami S, Igarashi N, Shimura R, Matsubara H, Kasahara Y, Takiguchi Y, Kuriyama T. Angiotensinconverting enzyme gene polymorphisms and prognosis in chronic thromboembolic pulmonary hypertension. Circ J 2006;70: 1174-1179.
17. Eddahibi S, Chaouat A, Tu L, Chouaid C, Weitzenblum E, Housset B, Maitre B, Adnot S. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:475-476.
18. Somvanshi PR, Venkatesh KV. A conceptual review on systems biology in health and diseases: from biological networks to modern therapeutics. Syst Synth Biol 2014;8:99-116.